A Drug's Rocky Road To Discovery May Signal Pancreatic Cancer Breakthrough

A Drug's Rocky Road To Discovery May Signal Pancreatic Cancer Breakthrough The New York Times reports on daraxonrasib, the first drug to substantially extend the lives of patients with pancreatic cancer. The cellular proteins it targets fuel the three leading causes of cancer deaths: pancreatic tumors, lung, and colon cancers. The drug is fast-tracked for review by the Food and Drug Administration and could win approval later this year. https://kffhealthnews.org/morning-breakout/cancer-2/